ICH E6(R3) Good Clinical Practice

R2 (2016) had patched R1 with risk-based monitoring and electronic records language, but the architecture remained a 1996 framework. R3 is a structural rewrite. The guideline is reorganised into an Overarching Principles section, an Annex 1 on Interventional Clinical Trials, and (planned) Annex 2 on Non-Traditional Interventional and Non-Interventional Studies.

• Principles first, prescription second — 12 overarching principles drive interpretation across trial designs.
• Quality by design (linking to ICH E8(R1)) — quality is built into protocol and process, not bolted on through monitoring.
• Technology-neutral — paper, electronic and hybrid records are addressed by the same expectations.
• Decentralised, hybrid and remote elements explicitly accommodated.
• Investigator and sponsor responsibilities clarified around delegated service providers and data flows.
• Risk-proportionate oversight and monitoring — not 100% SDV by default.
• Participant-centric framing — informed consent and trial conduct articulated around the participant, not the document.

1. Clinical trials should be conducted in accordance with ethical principles.
2. Trials should be designed, planned, conducted, recorded, overseen and reported in accordance with scientific principles.
3. Trials should be designed and conducted to ensure the rights, safety and well-being of participants.
4. Trials should have anticipated benefit that justifies the risks.
5. Trials should have a clear, concise and operationally feasible protocol.
6. Trials should be subject to objective review and approval (IRB/IEC, regulatory authority).
7. Medical decisions for participants should be the responsibility of a qualified physician.
8. Individuals involved in conducting the trial should be qualified by education, training and experience.
9. Informed consent should be freely given by every participant (or legally authorised representative).
10. Trial-related medical decisions and trial data should be reliable.
11. Trials should be conducted to ensure the quality of the data is fit for purpose.
12. Roles and responsibilities should be clear and documented.

• Quality management is a process, not a binder. Critical-to-quality factors must be identified, controls designed, risks assessed and the plan operationalised across the trial — and revisited as the trial evolves.
• Service provider oversight is explicit. Whether a CRO, eCOA vendor, central lab or home-nursing provider, the sponsor's qualification, contractual definition of responsibilities, and ongoing oversight is in scope.
• Computerised systems used in the trial (EDC, IRT, eCOA, eConsent, eTMF, lab systems, wearables platforms) must meet GCP-equivalent controls — validation, access control, audit trail, data integrity, change management — with documentation proportionate to risk.
• Monitoring is risk-based by default. The Risk Assessment / Monitoring Plan documents what is monitored centrally, what is monitored on-site, what triggers escalation and how SDV/SDR is targeted to critical data.
• Protocol deviations are managed in a quality-system frame, not as binary findings — the analysis question is whether the deviation matters for participant safety, data reliability or the primary endpoint.

• The investigator remains responsible for medical decisions and protocol compliance at the site, but the supervision of remote elements (home visits, televisits, direct-to-patient drug shipment) is explicitly part of that responsibility.
• Source data may be electronic and may originate outside the site (wearable device, patient app, central lab, home-nursing visit) — investigator oversight extends to the chain of custody of those data.
• Investigator delegation must match the qualifications of the delegate; the delegation log evolves as the trial evolves.
• Informed consent processes accommodate eConsent and remote consent, with documented confirmation of participant comprehension.

E6(R3) reinforces ALCOA+ principles for clinical data (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available) across electronic and paper records. Where data are first captured electronically and never exist on paper (eSource), the electronic capture is the source — there is no expectation to print and re-sign. Audit trails must be implemented in computerised systems used in the trial and must be available for review by monitors, auditors and inspectors.

Consent is framed as a process, not a signature. R3 explicitly accommodates eConsent — including remote signature, multimedia content, comprehension verification and digital records — provided the local regulatory framework permits. Recontact for new information arising during the trial is articulated as part of the ongoing consent process rather than a separate event.

• ICH Step 4 — adopted January 2025.
• EMA — adopted into EU regulatory framework Q3 2025; the EU Clinical Trials Regulation (CTR, Reg. 536/2014) overlays additional EU-specific obligations.
• FDA — final guidance issued 2025 superseding the May 2023 draft; effective dates for trials initiated after the implementation milestone.
• PMDA, Health Canada, MHRA, Swissmedic — adoption tracked through 2025–2026 with national notices.
• Trials in active conduct under E6(R2) generally continue under R2 to completion; new trials initiated after the regional adoption date follow R3.

1. Rewrite the sponsor's quality management approach around critical-to-quality factors and risk-proportionate controls, with linkage to ICH E8(R1).
2. Update SOPs from prescriptive R2 step-lists to principles-anchored procedures that allow risk-proportionate execution.
3. Catalogue computerised systems used in trials; confirm GCP-equivalent validation, access control, audit trail and data-integrity controls.
4. Update service-provider qualification, contracts and oversight to reflect the explicit R3 expectations.
5. Modernise monitoring plans to risk-based-by-default with targeted SDV/SDR.
6. Update informed-consent templates and processes for eConsent where used.
7. Train clinical-operations, data-management, quality and pharmacovigilance teams on the principles-first framing.